Aratana Proposes Public Offering - Analyst Blog

By
A A A

Aratana Therapeutics, Inc . ( PETX ) announced that it has initiated a public offering of 5,500,000 shares of its common stock. Aratana is offering 81.8% of the shares while the remaining are offered by certain stockholders. Underwriters have been granted an option to purchase an additional 825,000 shares of Aratana's common stock, with a 30-day window to do so.

We believe that Aratana, a biopharmaceutical company focused exclusively on pet therapeutics, will most likely use the funds for the development of its pipeline. 

Since 2010, Aratana has in-licensed three compounds, namely, AT-001 (pain in dogs and cats), AT-002 (inappetence in dogs and cats) and AT-003 (post-surgical pain in dogs and cats).

In Nov 2013, Aratana announced positive top-line results from its pivotal dose-ranging study on AT-001. Results revealed that significant improvement in pain assessment scores were observed in dogs receiving AT-001 compared to those on placebo. Aratana now plans to advance AT-001 into a pivotal field effectiveness study in 2014. Aratana expects positive results from the pivotal field effectiveness study will allow the company to seek marketing approval of the candidate. Aratana intends to commercialize AT-001 in 2016.

Aratana has initiated a pivotal field effectiveness study on AT-002. Top-line results from the study are expected in the first half of 2015 with approval expected in 2016. Aratana also intends to initiate a pilot field study on AT-003 in client-owned dogs this year.

Aratana carries a Zacks Rank #4 (Sell). Some better-ranked players in the pharma industry include Actelion Ltd. ( ALIOF ), Endocyte, Inc. ( ECYT ) and Lannett Co. Inc. ( LCI ). All the three stocks carry a Zacks Rank #1 (Strong Buy).



ACTELION LTD (ALIOF): Get Free Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

ARATANA THERAP (PETX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , ECYT , LCI , PETX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

65,878,391
  • $102.25 ▲ 0.12%
60,267,006
  • $16.01 ▼ 1.17%
45,656,511
  • $13.11 ▼ 4.17%
34,766,553
  • $49.43 ▲ 2.85%
34,661,727
  • $3.60 ▲ 0.28%
29,041,259
  • $19.12 ▼ 0.47%
21,343,464
  • $73.855 ▼ 1.04%
19,552,720
  • $10.85 ▼ 3.13%
As of 8/28/2014, 04:03 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com